Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
News|Videos|December 18, 2024
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
Author(s)Aditya Bardia, MD, MPH, FASCO
Dr. Aditya Bardia presents real-world findings on elacestrant, demonstrating prolonged real-world progression-free survival (rwPFS) in ER+/HER2- advanced breast cancer patients across all clinically relevant subgroups, with benefits observed particularly in earlier treatment lines and in those without prior fulvestrant exposure.
Advertisement
Advertisement
Related to this article
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
Roswell Park Comprehensive Cancer Center recognized members of its clinical, research and healthcare teams during the second annual Excellence Awards.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
China's NMPA Approves Pirtobrutinib Across CLL
4
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
5